About Plasminogen activator inhibitor 2
Plasminogen activator inhibitor 2 (SERPINB2) is a protein
from Homo sapiens identified by UniProt accession
P05120, 415 residues long.
MolForge cross-references it against 0 known binders and
562 disease associations.
Target properties
| Protein name | Plasminogen activator inhibitor 2 |
|---|
| UniProt accession | P05120 |
|---|
| Gene | SERPINB2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 415 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (562)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.27
- neutrophil count · score 0.18
- genetic disorder · score 0.12
- neoplasm · score 0.11
- breast cancer · score 0.09
- cancer · score 0.09
- Blackfan-Diamond anemia · score 0.07
- X-linked severe congenital neutropenia · score 0.07
- hepatocellular carcinoma · score 0.07
- cholangiocarcinoma · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P05120-F1 | alphafold | PREDICTED | 85.49 | — |
Amino-acid sequence (415 residues)
MEDLCVANTL FALNLFKHLA KASPTQNLFL SPWSISSTMA MVYMGSRGST EDQMAKVLQF NEVGANAVTP MTPENFTSCG FMQQIQKGSY PDAILQAQAA DKIHSSFRSL SSAINASTGN YLLESVNKLF GEKSASFREE YIRLCQKYYS SEPQAVDFLE CAEEARKKIN SWVKTQTKGK IPNLLPEGSV DGDTRMVLVN AVYFKGKWKT PFEKKLNGLY PFRVNSAQRT PVQMMYLREK LNIGYIEDLK AQILELPYAG DVSMFLLLPD EIADVSTGLE LLESEITYDK LNKWTSKDKM AEDEVEVYIP QFKLEEHYEL RSILRSMGME DAFNKGRANF SGMSERNDLF LSEVFHQAMV DVNEEGTEAA AGTGGVMTGR TGHGGPQFVA DHPFLFLIMH KITNCILFFG RFSSP
Explore Plasminogen activator inhibitor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets